India's Richest People 2026 edition · 1 director · Source: Hurun India
- #1,174 Vasant Laxminarayan Rathi ₹2,100 Cr
Market Cap
₹2,909 Cr
ADVENZYMES · NSE
Share Price
₹264.15
+1.69% today
Revenue
₹746 Cr
FY 2025-26 · +17.1% YoY
EBITDA
₹225 Cr
Margin 30.2%
Net Profit
₹155 Cr
FY 2025-26 · +18.2% YoY
P/E (TTM)
17.9x
P/B 1.7x
ROE
11.4%
ROCE 15.1%
Debt / Equity
0.02
Interest cover 2.0x
About Advanced Enzyme Technologies Limited
Data last updated:
Advanced Enzyme Technologies Limited is a public limited company based in Thane, Maharashtra, India. It operates in the industrial enzymes and biochemicals segment of the chemicals and materials sector. It was incorporated on 15 March 1989 and has been in existence for over 37 years.
Its director Vasant Laxminarayan Rathi is #1,174 among India's richest people (2026).
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L24200MH1989PLC051018. Its GSTIN is 27AABCA4555E1ZX (Maharashtra). The company holds 3 GST registrations, all of them active. It is a listed company as per MCA records. Its shares are listed on BSE: 540025 and NSE: ADVENZYMES.
The company has an authorised share capital of ₹35 Cr and a paid-up capital of ₹22.4 Cr. It was formerly known as Advanced Biochemicals Private Limited and Advanced Biochemicals Limited. It is led by directors including Mukund Madhusudan Kabra (Whole-Time Director) and Vinodkumar Hiralal Jajoo.
Its last annual general meeting (AGM) was held on 31 July 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Sun Magnectica 5th Floor Near Lic Service Road Louis Wadi, Thane, Maharashtra, India – 400604.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹745.76 Cr, a growth of 17.1% compared to the previous year. For the same year it recorded a net profit of ₹154.61 Cr (net margin 20.7%) and EBITDA of ₹225.38 Cr (EBITDA margin 30.2%). The net worth stands at ₹1,631.96 Cr (up 14.9% YoY). Total assets are valued at ₹1,720.52 Cr (up 13.9% YoY).
The company has about 462 employees on its provident fund (EPFO) records. Its group structure includes 3 subsidiaries.
The company is associated with 1 brand: Advanced Enzyme Technologies. As per MCA filings, the company has open charges of ₹30 Cr and satisfied charges of ₹218.5 Cr on record. Court records list 31 cases involving the company, including 25 filed by the company and 6 filed against it; 3 cases are pending. The company has 28 deals on record (24 market trades, 2 secondary share transfers, 1 ipo), with disclosed funding of ₹30 Cr; the latest was in August 2025. Its 3 peer companies in the Chemicals industry (Enzymes), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 1 larger and 2 smaller; the largest is Novozymes South Asia Private Limited with revenue of ₹1,392.5 Cr. The company has 13 MSME Form 1 returns on record between 2019 and 2024, listing 142 overdue payments to 59 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website advancedenzymes.com.
Company details
CIN L24200MH1989PLC051018
Registration Number 051018
Incorporation Date 15 March 1989
ROC Mumbai
Listing Status Listed - Listed on NSE (ADVENZYMES); Listed on BSE (540025)
Company Status Active
Date of Last AGM 31 July 2026
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
Name history
Advanced Enzyme Technologies has undergone 2 name changes throughout its history. The company was previously known as Advanced Biochemicals Private Limited, and Advanced Biochemicals Limited. The current legal name is Advanced Enzyme Technologies Limited.
| Company Name | Status |
|---|---|
| Advanced Enzyme Technologies Limited | Current |
| Advanced Biochemicals Private Limited | Previous |
| Advanced Biochemicals Limited | Previous |
CIN history
Advanced Enzyme Technologies has one previous CIN (Corporate Identification Number): U24200MH1989PLC051018. The current CIN is L24200MH1989PLC051018, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24200MH1989PLC051018 | Current |
| U24200MH1989PLC051018 | Previous |
Key People
Mukund Madhusudan Kabra Whole-Time Director Vinodkumar Hiralal Jajoo Director Rasika Vasant Rathi Director Recognitions & Rankings of Advanced Enzyme Technologies
Contact details
Advanced Enzyme Technologies Limited's registered office is in Thane, Maharashtra. Its website is advancedenzymes.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressSun Magnectica 5th Floor Near Lic Service Road Louis Wadi, Thane, Maharashtra, India – 400604
- IndustryChemicals and Materials, Industrial Enzymes & Biochemicals
To see the full contact details of Advanced Enzyme Technologies Limited, buy the company report.
Comprehensive company report
Advanced Enzyme Technologies Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Advanced Enzyme Technologies operates one associated brand: Advanced Enzyme Technologies. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Enzymes are manufactured for nutrition, food, feed, and textile industries. | advancedenzymes.com |
Business activity
The main business activity of Advanced Enzyme Technologies is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Advanced Enzyme Technologies Limited, buy the company report.
Financials of Advanced Enzyme Technologies Limited
FY 2025-26 filings availableAdvanced Enzyme Technologies Limited reported revenue of ₹745.76 Cr (up 17.1% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue
₹746 Cr
+17.1% YoY
EBITDA
₹225 Cr
+15.3% YoY
Profit After Tax
₹155 Cr
+18.2% YoY
Net Worth
₹1,632 Cr
+14.9% YoY
Total Assets
₹1,721 Cr
+13.9% YoY
Total Debt
₹32.01 Cr
-18.7% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 746 | 637 | 624 | 541 | 529 | 502 | 444 |
| Revenue growth | +17.1% | +2.1% | +15.4% | +2.1% | +5.5% | +13.0% | - |
| EBITDA | 225 | 196 | 191 | 153 | 203 | 232 | 203 |
| EBITDA margin | +30.2% | +30.7% | +30.5% | +28.4% | +38.3% | +46.3% | +45.8% |
| Profit before tax | 233 | 187 | 188 | 140 | 171 | 210 | 179 |
| Net profit | 155 | 131 | 144 | 109 | 119 | 146 | 129 |
| Net profit margin | +20.7% | +20.5% | +23.1% | +20.2% | +22.4% | +29.0% | +29.1% |
| EPS (₹) | 15.07 | 11.72 | 11.92 | 9.45 | 10.70 | 13.08 | 11.58 |
| Balance sheet | |||||||
| Total assets | 1,721 | 1,510 | 1,419 | 1,318 | 1,176 | 1,055 | 902 |
| Net worth | 1,632 | 1,421 | 1,324 | 1,235 | 1,089 | 971 | 840 |
| Total debt | 32.01 | 39.35 | 47.31 | 33.50 | 34.74 | 22.63 | 27.80 |
| Cash & bank | 116 | 108 | 127 | 123 | 274 | 198 | 83.02 |
| Net working capital | 373 | 322 | 325 | 296 | 450 | 336 | 208 |
| Cash flow | |||||||
| Cash from operations | 157 | 142 | 141 | 140 | 122 | 163 | 141 |
| Cash from investing | (71.88) | (89.48) | (64.80) | (286) | 1.65 | (27.33) | (42.74) |
| Cash from financing | (70.37) | (72.54) | (59.24) | (25.80) | (48.50) | (26.31) | (38.55) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 190 | 203 | 172 | 185 | 186 | 167 | 169 | 146 |
| Revenue growth (YoY) | +2.1% | +21.7% | +1.7% | +26.3% | +20.3% | - | - | - |
| Other income | 13.02 | 7.34 | 19.72 | 10.28 | 8.85 | 8.75 | 7.69 | 9.62 |
| EBITDA | 50.97 | 63.23 | 49.35 | 60.06 | 56.43 | 45.60 | 55.25 | 42.42 |
| EBITDA margin | +26.9% | +31.1% | +28.7% | +32.5% | +30.4% | +27.3% | +32.7% | +29.0% |
| Depreciation | 9.88 | 10.19 | 10.21 | 10.08 | 9.62 | 10.08 | 8.97 | 8.90 |
| Interest | 0.58 | 0.57 | 0.57 | 0.72 | 0.76 | 0.81 | 0.94 | 0.93 |
| Profit before tax | 53.53 | 59.81 | 58.29 | 59.54 | 54.90 | 43.46 | 53.03 | 42.21 |
| Tax | 14.94 | 14.55 | 15.11 | 14.81 | 14.46 | 16.73 | 14.14 | 8.81 |
| Net profit | 38.59 | 45.26 | 43.18 | 44.73 | 40.44 | 26.73 | 38.89 | 33.40 |
| EPS (₹) | 3.31 | 3.84 | 3.79 | 3.87 | 3.57 | 2.37 | 3.36 | 2.93 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 453 | 351 | 365 | 312 | 273 | 283 | 247 |
| Revenue growth | +28.8% | -3.9% | +17.3% | +14.2% | -3.8% | +14.6% | - |
| EBITDA | 107 | 70.94 | 86.46 | 75.09 | 72.82 | 101 | 76.95 |
| EBITDA margin | +23.6% | +20.2% | +23.7% | +24.1% | +26.7% | +35.6% | +31.1% |
| Profit before tax | 158 | 121 | 134 | 74.29 | 72.07 | 98.44 | 75.85 |
| Net profit | 135 | 102 | 123 | 56.13 | 53.62 | 70.52 | 57.95 |
| Net profit margin | +29.8% | +29.1% | +33.7% | +18.0% | +19.7% | +24.9% | +23.4% |
| EPS (₹) | 11.78 | 9.15 | 9.67 | 4.97 | 4.88 | 6.36 | 5.19 |
| Balance sheet | |||||||
| Total assets | 716 | 633 | 583 | 528 | 483 | 437 | 387 |
| Net worth | 710 | 629 | 580 | 525 | 480 | 435 | 370 |
| Total debt | 1.95 | 2.76 | 1.50 | 2.25 | 1.58 | 0.90 | 9.77 |
| Cash & bank | 2.35 | 5.83 | 2.02 | 24.72 | 17.98 | 1.87 | 3.03 |
| Net working capital | 148 | 152 | 158 | 137 | 124 | 87.04 | 97.54 |
| Cash flow | |||||||
| Cash from operations | 88.73 | 63.48 | 51.63 | 50.30 | 37.10 | 84.19 | 45.98 |
| Cash from investing | (34.19) | (1.74) | (2.70) | (42.35) | (14.24) | (69.91) | (24.94) |
| Cash from financing | (58.25) | (57.63) | (56.88) | (11.99) | (10.87) | (15.45) | (18.56) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 116 | 116 | 95.58 | 116 | 125 | 87.21 | 101 | 77.38 |
| Revenue growth (YoY) | -7.3% | +33.5% | -5.2% | +49.6% | +45.4% | - | - | - |
| Other income | 2.29 | 5.16 | 1.29 | 3.08 | 53.85 | 4.53 | 1.43 | 1.66 |
| Total expenses | 85.45 | 89.56 | 75.98 | 86.16 | 94.50 | 73.04 | 78.81 | 63.85 |
| EBITDA | 30.41 | 26.85 | 19.60 | 29.59 | 30.52 | 14.17 | 22.06 | 13.53 |
| EBITDA margin | +26.2% | +23.1% | +20.5% | +25.6% | +24.4% | +16.2% | +21.9% | +17.5% |
| Depreciation | 2.92 | 3.12 | 3.04 | 3.00 | 2.93 | 3.11 | 2.89 | 2.78 |
| Interest | 0.04 | 0.06 | 0.05 | 0.05 | 0.05 | 0.08 | 0.06 | 0.08 |
| Profit before tax | 29.74 | 28.83 | 17.80 | 29.62 | 81.39 | 15.51 | 20.54 | 12.33 |
| Tax | 7.39 | 6.55 | 4.57 | 7.33 | 7.41 | 4.46 | 5.36 | 3.20 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 29 Oct 2026
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 190 | 203 | 172 | 185 | 186 | 167 | 169 | 146 |
| Revenue growth (YoY) | +2.1% | +21.7% | +1.7% | +26.3% | +20.3% | - | - | - |
| Other income | 13.02 | 7.34 | 19.72 | 10.28 | 8.85 | 8.75 | 7.69 | 9.62 |
| EBITDA | 50.97 | 63.23 | 49.35 | 60.06 | 56.43 | 45.60 | 55.25 | 42.42 |
| EBITDA margin | +26.9% | +31.1% | +28.7% | +32.5% | +30.4% | +27.3% | +32.7% | +29.0% |
| Depreciation | 9.88 | 10.19 | 10.21 | 10.08 | 9.62 | 10.08 | 8.97 | 8.90 |
| Interest | 0.58 | 0.57 | 0.57 | 0.72 | 0.76 | 0.81 | 0.94 | 0.93 |
| Profit before tax | 53.53 | 59.81 | 58.29 | 59.54 | 54.90 | 43.46 | 53.03 | 42.21 |
| Tax | 14.94 | 14.55 | 15.11 | 14.81 | 14.46 | 16.73 | 14.14 | 8.81 |
| Net profit | 38.59 | 45.26 | 43.18 | 44.73 | 40.44 | 26.73 | 38.89 | 33.40 |
| EPS (₹) | 3.31 | 3.84 | 3.79 | 3.87 | 3.57 | 2.37 | 3.36 | 2.93 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 746 | 637 | 624 | 541 | 529 | 502 | 444 |
| Revenue growth | +17.1% | +2.1% | +15.4% | +2.1% | +5.5% | +13.0% | - |
| Other income | 50.97 | 33.04 | 36.66 | 25.46 | 6.42 | 8.85 | 5.64 |
| Total expenses | 520 | 441 | 433 | 387 | 327 | 269 | 241 |
| Employee cost | 162 | 142 | 128 | 115 | 104 | 87.11 | 80.19 |
| EBITDA | 225 | 196 | 191 | 153 | 203 | 232 | 203 |
| EBITDA margin | +30.2% | +30.7% | +30.5% | +28.4% | +38.3% | +46.3% | +45.8% |
| Depreciation | 40.09 | 36.56 | 35.24 | 35.03 | 34.98 | 28.41 | 25.78 |
| Interest | 3.73 | 4.63 | 4.12 | 3.48 | 2.96 | 2.56 | 4.08 |
| Profit before tax | 233 | 187 | 188 | 140 | 171 | 210 | 179 |
| Tax | 58.93 | 53.40 | 50.87 | 36.52 | 47.26 | 58.91 | 46.11 |
| Net profit | 155 | 131 | 144 | 109 | 119 | 146 | 129 |
| Net profit margin | +20.7% | +20.5% | +23.1% | +20.2% | +22.4% | +29.0% | +29.1% |
| EPS (₹) | 15.07 | 11.72 | 11.92 | 9.45 | 10.70 | 13.08 | 11.58 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 22.39 | 22.38 | 22.37 | 22.37 | 22.36 | 22.35 | 22.34 |
| Reserves & surplus | 1,609 | 1,398 | 1,302 | 1,213 | 1,066 | 948 | 817 |
| Shareholders' funds (net worth) | 1,632 | 1,421 | 1,324 | 1,235 | 1,089 | 971 | 840 |
| Minority interest | 51.17 | 47.81 | 46.95 | 49.10 | 51.79 | 60.11 | 27.80 |
| Secured loans | 20.53 | 21.54 | 25.11 | 13.24 | 10.77 | 18.35 | 18.48 |
| Unsecured loans | 11.48 | 17.81 | 22.20 | 20.26 | 23.97 | 4.28 | 9.32 |
| Total debt | 32.01 | 39.35 | 47.31 | 33.50 | 34.74 | 22.63 | 27.80 |
| Total liabilities | 1,721 | 1,510 | 1,419 | 1,318 | 1,176 | 1,055 | 902 |
| Assets | |||||||
| Gross block | 1,018 | 966 | 902 | 868 | 806 | 753 | 681 |
| Net block | 692 | 679 | 650 | 649 | 619 | 601 | 563 |
| Capital work in progress | 51.17 | 21.71 | 41.10 | 21.50 | 15.07 | 10.42 | 10.13 |
| Investments | 584 | 480 | 403 | 360 | 102 | 121 | 124 |
| Inventories | 177 | 157 | 148 | 124 | 121 | 93.88 | 80.03 |
| Sundry debtors | 145 | 115 | 98.57 | 100 | 88.21 | 86.27 | 74.69 |
| Cash & bank balances | 116 | 108 | 127 | 123 | 274 | 198 | 83.02 |
| Loans & advances | 21.52 | 19.23 | 32.93 | 14.88 | 19.73 | 16.82 | 14.31 |
| Total current assets | 460 | 400 | 407 | 363 | 502 | 395 | 252 |
| Total current liabilities | 86.37 | 77.81 | 81.87 | 66.44 | 52.17 | 58.36 | 43.72 |
| Net working capital | 373 | 322 | 325 | 296 | 450 | 336 | 208 |
| Total assets | 1,721 | 1,510 | 1,419 | 1,318 | 1,176 | 1,055 | 902 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 94.23 | 114 | 96.42 | 267 | 192 | 82.66 | 23.06 |
| Net cash from operating activities | 157 | 142 | 141 | 140 | 122 | 163 | 141 |
| Net cash from investing activities | (71.88) | (89.48) | (64.80) | (286) | 1.65 | (27.33) | (42.74) |
| Net cash from financing activities | (70.37) | (72.54) | (59.24) | (25.80) | (48.50) | (26.31) | (38.55) |
| Net change in cash | 14.53 | (19.53) | 17.33 | (171) | 75.44 | 109 | 59.60 |
| Closing cash | 116 | 108 | 127 | 123 | 274 | 198 | 83.02 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +17.1% | +2.1% | +15.4% | +2.1% | +5.5% | +13.0% | - |
| EBITDA growth | +15.3% | +2.6% | +24.2% | -24.3% | -12.9% | +14.3% | - |
| PBT growth | +24.1% | -0.2% | +33.8% | -17.9% | -18.7% | +17.4% | +10.6% |
| Net income growth | +18.2% | -9.2% | +32.2% | -8.3% | -18.5% | +12.7% | - |
| Revenue CAGR (3Y) | +11.3% | +6.4% | +7.5% | +6.8% | +8.1% | +8.7% | +10.5% |
| EBITDA CAGR (3Y) | +13.7% | -1.2% | -6.4% | -9.0% | +3.4% | +12.1% | +10.3% |
| Profitability & leverage | |||||||
| Net income margin | +23.3% | +21.0% | +22.0% | +19.2% | +23.4% | +30.2% | +30.0% |
| Return on capital employed | +15.1% | +13.6% | +14.5% | +12.0% | +16.4% | +22.8% | +23.0% |
| Return on net worth | +11.4% | +9.8% | +10.7% | +8.9% | +12.0% | +16.7% | +17.5% |
| Debt / equity | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 |
| Long-term debt / equity | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 |
| Interest cover | 2.01 | 2.91 | 2.65 | 2.94 | 1.77 | 1.25 | 2.30 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.75 | 0.68 | 0.70 | 0.65 | 0.68 | 0.70 | 0.70 |
| Inventory turnover | 4.46 | 4.17 | 4.58 | 4.42 | 4.93 | 5.77 | 5.66 |
| Debtors turnover | 5.73 | 5.95 | 6.27 | 5.73 | 6.07 | 6.24 | 6.66 |
| EPS (₹) | 15.07 | 11.72 | 11.92 | 9.45 | 10.70 | 13.08 | 11.58 |
| Dividend per share (₹) | 5.35 | 5.20 | 5.10 | 1.00 | 1.00 | 0.90 | 0.60 |
| Book value per share (₹) | 145.79 | 127.00 | 118.41 | 110.45 | 97.37 | 86.88 | 75.18 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 116 | 116 | 95.58 | 116 | 125 | 87.21 | 101 | 77.38 |
| Revenue growth (YoY) | -7.3% | +33.5% | -5.2% | +49.6% | +45.4% | - | - | - |
| Other income | 2.29 | 5.16 | 1.29 | 3.08 | 53.85 | 4.53 | 1.43 | 1.66 |
| Total expenses | 85.45 | 89.56 | 75.98 | 86.16 | 94.50 | 73.04 | 78.81 | 63.85 |
| EBITDA | 30.41 | 26.85 | 19.60 | 29.59 | 30.52 | 14.17 | 22.06 | 13.53 |
| EBITDA margin | +26.2% | +23.1% | +20.5% | +25.6% | +24.4% | +16.2% | +21.9% | +17.5% |
| Depreciation | 2.92 | 3.12 | 3.04 | 3.00 | 2.93 | 3.11 | 2.89 | 2.78 |
| Interest | 0.04 | 0.06 | 0.05 | 0.05 | 0.05 | 0.08 | 0.06 | 0.08 |
| Profit before tax | 29.74 | 28.83 | 17.80 | 29.62 | 81.39 | 15.51 | 20.54 | 12.33 |
| Tax | 7.39 | 6.55 | 4.57 | 7.33 | 7.41 | 4.46 | 5.36 | 3.20 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 453 | 351 | 365 | 312 | 273 | 283 | 247 |
| Revenue growth | +28.8% | -3.9% | +17.3% | +14.2% | -3.8% | +14.6% | - |
| Other income | 63.39 | 61.49 | 58.81 | 9.81 | 9.08 | 6.82 | 9.00 |
| Total expenses | 346 | 280 | 279 | 236 | 200 | 183 | 170 |
| Employee cost | 64.73 | 56.04 | 49.39 | 41.42 | 39.32 | 34.23 | 32.61 |
| EBITDA | 107 | 70.94 | 86.46 | 75.09 | 72.82 | 101 | 76.95 |
| EBITDA margin | +23.6% | +20.2% | +23.7% | +24.1% | +26.7% | +35.6% | +31.1% |
| Depreciation | 12.08 | 11.41 | 10.90 | 10.28 | 9.56 | 8.93 | 8.81 |
| Interest | 0.50 | 0.51 | 0.39 | 0.33 | 0.27 | 0.22 | 1.29 |
| Profit before tax | 158 | 121 | 134 | 74.29 | 72.07 | 98.44 | 75.85 |
| Tax | 25.87 | 18.11 | 25.87 | 18.75 | 17.56 | 27.41 | 17.90 |
| Net profit | 135 | 102 | 123 | 56.13 | 53.62 | 70.52 | 57.95 |
| Net profit margin | +29.8% | +29.1% | +33.7% | +18.0% | +19.7% | +24.9% | +23.4% |
| EPS (₹) | 11.78 | 9.15 | 9.67 | 4.97 | 4.88 | 6.36 | 5.19 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 22.39 | 22.38 | 22.37 | 22.37 | 22.36 | 22.35 | 22.34 |
| Reserves & surplus | 687 | 607 | 558 | 503 | 458 | 413 | 348 |
| Shareholders' funds (net worth) | 710 | 629 | 580 | 525 | 480 | 435 | 370 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.19 | 8.07 |
| Unsecured loans | 1.95 | 2.76 | 1.50 | 2.24 | 1.58 | 0.71 | 1.70 |
| Total debt | 1.95 | 2.76 | 1.50 | 2.25 | 1.58 | 0.90 | 9.77 |
| Total liabilities | 716 | 633 | 583 | 528 | 483 | 437 | 387 |
| Assets | |||||||
| Gross block | 243 | 238 | 213 | 204 | 187 | 173 | 160 |
| Net block | 151 | 156 | 142 | 143 | 132 | 131 | 127 |
| Capital work in progress | 48.69 | 20.75 | 21.86 | 11.03 | 8.68 | 7.34 | 9.96 |
| Investments | 345 | 290 | 256 | 201 | 189 | 184 | 121 |
| Inventories | 117 | 101 | 96.88 | 76.79 | 80.08 | 63.42 | 59.65 |
| Sundry debtors | 94.32 | 78.17 | 75.17 | 66.67 | 49.09 | 54.74 | 51.89 |
| Cash & bank balances | 2.35 | 5.83 | 2.02 | 24.72 | 17.98 | 1.87 | 3.03 |
| Loans & advances | 11.73 | 10.10 | 23.47 | 5.37 | 12.86 | 7.32 | 9.80 |
| Total current assets | 225 | 196 | 198 | 174 | 160 | 127 | 124 |
| Total current liabilities | 76.93 | 43.40 | 39.60 | 36.09 | 35.67 | 40.31 | 26.83 |
| Net working capital | 148 | 152 | 158 | 137 | 124 | 87.04 | 97.54 |
| Total assets | 716 | 633 | 583 | 528 | 483 | 437 | 387 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 5.60 | 1.50 | 9.45 | 13.50 | 1.51 | 2.67 | 0.19 |
| Net cash from operating activities | 88.73 | 63.48 | 51.63 | 50.30 | 37.10 | 84.19 | 45.98 |
| Net cash from investing activities | (34.19) | (1.74) | (2.70) | (42.35) | (14.24) | (69.91) | (24.94) |
| Net cash from financing activities | (58.25) | (57.63) | (56.88) | (11.99) | (10.87) | (15.45) | (18.56) |
| Net change in cash | (3.71) | 4.11 | (7.95) | (4.05) | 11.99 | (1.16) | 2.48 |
| Closing cash | 2.35 | 5.83 | 2.02 | 24.72 | 17.98 | 1.87 | 3.03 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +28.8% | -3.9% | +17.3% | +14.2% | -3.8% | +14.6% | - |
| EBITDA growth | +50.6% | -18.0% | +15.1% | +3.1% | -27.7% | +31.0% | - |
| PBT growth | +30.8% | -10.1% | +80.4% | +3.1% | -26.8% | +29.8% | +60.6% |
| Net income growth | +32.0% | -17.0% | +119.6% | +4.7% | -24.0% | +21.7% | - |
| Revenue CAGR (3Y) | +13.3% | +8.8% | +8.8% | +8.0% | +7.1% | +10.2% | +12.7% |
| EBITDA CAGR (3Y) | +12.5% | -0.9% | -5.0% | -0.8% | +11.3% | +26.3% | +16.6% |
| Profitability & leverage | |||||||
| Net income margin | +29.1% | +29.1% | +29.6% | +17.8% | +20.0% | +25.1% | +23.4% |
| Return on capital employed | +23.5% | +19.9% | +27.6% | +14.8% | +15.7% | +23.9% | +21.1% |
| Return on net worth | +19.7% | +16.9% | +22.3% | +11.0% | +11.9% | +17.6% | +16.8% |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.04 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 0.53 | 0.86 | 0.52 | 0.51 | 0.43 | 0.24 | 1.89 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.88 | 1.56 | 1.76 | 1.60 | 1.52 | 1.70 | 1.76 |
| Inventory turnover | 4.15 | 3.54 | 4.21 | 3.97 | 3.80 | 4.61 | 4.18 |
| Debtors turnover | 5.25 | 4.58 | 5.15 | 5.38 | 5.25 | 5.32 | 5.49 |
| EPS (₹) | 11.78 | 9.15 | 9.67 | 4.97 | 4.88 | 6.36 | 5.19 |
| Dividend per share (₹) | 5.35 | 5.20 | 5.10 | 1.00 | 1.00 | 0.90 | 0.60 |
| Book value per share (₹) | 63.38 | 56.25 | 51.91 | 46.98 | 42.97 | 38.97 | 33.17 |
To see the full year-wise statements and ratios of Advanced Enzyme Technologies Limited, buy the company report.
Board of directors of Advanced Enzyme Technologies Limited
Advanced Enzyme Technologies has 9 current directors and 14 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Mukund Madhusudan Kabra Also directs: Saiganesh Enzytech Solutions Private Limited, Advanced Bio-Agro Tech Limited, Advanced Enzytech Solutions Limited and 2 more | Whole-Time Director | 04 Sep 1999 | 27 Years 1 Months | Current |
| Vinodkumar Hiralal Jajoo | Director | 09 Feb 2019 | 7 Years 8 Months | Current |
| Rasika Vasant Rathi Also directs: Scitech Specialities Private Limited | Director | 08 Jan 2019 | 7 Years 9 Months | Current |
| Sunny Sharma Also directs: Marksans Pharma Limited, Arcatron Mobility Private Limited, Lattice Medtech Private Limited and 5 more | Director | 02 Nov 2019 | 6 Years 11 Months | Current |
| Pramod Kasat Also directs: JC Biotech Private Limited, Sai Silks (Kalamandir) Limited, Natural Capsules Limited and 5 more | Director | 14 Dec 2016 | 9 Years 10 Months | Current |
| Vasant Rathi | Director | 05 Mar 1993 | 33 Years 7 Months | Current |
Showing 6 of 9 current directors. View all directors
Peer comparison
Advanced Enzyme Technologies Limited is compared with the 3 companies closest to it by revenue in the Chemicals industry (Enzymes), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Novozymes South Asia Private Limited | ₹1,392.5 Cr (FY 2025) | 27.0% | Bangalore, Karnataka, India | |||
| Advanced Enzyme Technologies Limitedthis company | ₹745.76 Cr (FY 2026) | ₹154.61 Cr | 20.7% | 17.1% | 462 | Thane, Maharashtra, India |
| Guaran Chemicals Private Limited | ₹235.53 Cr (FY 2025) | 11.0% | Siwani, Haryana, India | |||
| Sanzyme Biologics Private Limited | ₹226.14 Cr (FY 2025) | 15.0% | Hyderabad, Telangana, India |
To see the full peer comparison of Advanced Enzyme Technologies Limited, buy the company report.
Auditor
Advanced Enzyme Technologies Limited is audited by M S K A & Associates for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| M S K A & Associates | FY 2023 | 105047W |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 43.20%, foreign institutional investors hold 26.70%, domestic institutional investors hold 4.80% and retail and other public shareholders hold 25.30%.
Sep 2026
QUARTER
43.20% Promoters
4.80% DII (Domestic Institutional)
26.70% FII (Foreign Institutional)
25.30% Retail & Others
Promoter holding - history
Now 43.20% · Sep 2026High 43.30% · Jun 2026Low 43.00% · Mar 2026
Shareholding trend - last 6 quarters
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 43.20% | 43.30% | 43.00% | 43.10% |
| Public | 56.80% | 56.70% | 57.00% | 56.90% |
Charges & borrowings
Open charges
₹30 Cr
Satisfied charges
₹218.5 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 28 Aug 2006 | 10021925 | Hdfc Bank Limited | ₹15 Cr | Open | |
| 22 Jun 2005 | 90146880 | Citi Bank N.A. | ₹15 Cr | Open | |
| 29 Jun 2022 | 100595179 | Axis Bank Limited | ₹5 Cr | Satisfied | |
| 10 Feb 2022 | 100542147 | Others | ₹10 Cr | Satisfied | |
| 25 Mar 2017 | 100092007 | Hdfc Bank Limited | ₹16.8 Lakh | Satisfied |
To see the full charge records of Advanced Enzyme Technologies Limited, buy the company report.
Total charge records: 30 View all charges
Deals & funding
Advanced Enzyme Technologies Limited has 28 deals on record (24 market trades, 2 secondary share transfers, 1 ipo), with disclosed funding of ₹30 Cr; the latest was in August 2025.
Total deals
28
Market trades
24
Secondary share transfers
2
IPO
1
Funding round
1
Disclosed funding
₹30 Cr
Deals on record (5 of 28)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Aug 2025 | Market trade | ₹79.7 Cr | Buyer: Polunin Emerging Markets Small Cap Fund Llc, Graviton Research Capital LLP Seller: Graviton Research Capital LLP |
| Sep 2024 | Market trade | ₹41.7 Cr | Buyer: Graviton Research Capital LLP Seller: Graviton Research Capital LLP |
| Dec 2023 | Market trade | ₹48.1 Cr | Buyer: Graviton Research Capital LLP Seller: Graviton Research Capital LLP , Advenza Global Limited |
| Jun 2023 | Market trade | ₹68.89 Cr | Buyer: Icici Prudential Mutual Fund Seller: Advenza Global Limited |
| Sep 2022 | Market trade | ₹78.62 Cr | Buyer: Nalanda India Equity Seller: Advenza Global Limited |
To see the full deal history of Advanced Enzyme Technologies Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Advanced Enzyme Technologies Limited has 31 court cases on record: 25 filed by Advanced Enzyme Technologies, 6 filed against it. 3 cases are pending and 28 are disposed.
Total cases
31
Filed by the company
25
Filed against the company
6
Pending
3
Disposed
28
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 31 | 6 | 3 |
Cases on record (5 of 31)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Thane, Maharashtra | Civil suit | Filed by the company against M/S.Shivek Labs Limited and 1 other | Pending |
| District court, Thane, Maharashtra | Civil suit | Filed by the company against Aman Agrawal Sogmatpru FPR Ion Healthcare Private Limited and 3 others | Disposed |
| District court, Thane, Maharashtra | Court case (Civil M.A.) | Filed by the company against M/S. Pure Foods Ltd. and 2 others | Disposed |
| District court, Thane, Maharashtra | Court case (Sum.Civ.Suit) | Filed by the company against Pure Foods Ltd and 2 | Disposed |
| District court, Thane, Maharashtra | Court case (Sum.Civ.Suit) | Filed by the company against Ms.Raikvaa Traders Pvt. Ltd. | Disposed |
To see the full case history of Advanced Enzyme Technologies Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Advanced Enzyme Technologies Limited was last rated by Crisil on 16 Oct 2020.
| Rating agency | Rated on | Rating |
|---|---|---|
| Crisil | 16 Oct 2020 |
To see the full credit ratings and regulatory alerts of Advanced Enzyme Technologies Limited, buy the company report.
MSME payment delays
Advanced Enzyme Technologies Limited has 13 MSME Form 1 returns on record between 2019 and 2024, listing 142 overdue payments to 59 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 59)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| Barcode Biosciences Private Limited | |||
| Pecopp Pest Control Services Private Limited | |||
| Sortd Ecommerce Solutions | |||
| an individual supplier |
To see the full MSME payment records of Advanced Enzyme Technologies Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Advanced Enzyme Technologies has 3 subsidiary companies. This group structure data is as of FY 2020. The table lists each entity with its relationship and holding.
3
Subsidiary companies
Key subsidiaries
| Company Name | CIN | Shares held |
|---|---|---|
| Advanced Bio-Agro Tech Limited | U24100MH2004PLC149464 | |
| Advanced Enzytech Solutions Limited | U24200MH2008PLC186383 | |
| JC Biotech Private Limited | U65993TG1991PTC013624 |
To see the full group structure of Advanced Enzyme Technologies Limited, buy the company report.
Employees & EPFO
Advanced Enzyme Technologies Limited has a workforce of 462 employees on its EPFO records as of Mar 28, 2024, across 1 active EPFO establishment.
Employee count
462
Active EPFO establishments
1
Employee growth
4.52%
GST
Advanced Enzyme Technologies has 3 GST registrations: 3 active.
Total GSTINs
3
Active
3
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AABCA4555E1ZX | Maharashtra | Active | 01 Jul 2017 |
| 27AABCA4555E2ZW | Maharashtra | Active | 30 Jul 2017 |
| 23AABCA4555E1Z5 | Madhya Pradesh | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Advanced Enzyme Technologies Limited, buy the company report.
Recent activity
Advanced Enzyme Technologies Limited has 35 board changes on record since 1993: 23 appointments and 12 cessations. The latest: Pradip Bhailal Shah was appointed as Director on 12 Jun 2026.
AGM
Advanced Enzyme Technologies Limited last Annual general meeting of members was held on 31 Jul 2026 as per latest MCA records.
Appointed
Pradip Bhailal Shah was appointed as Director.
Filing
Advanced Enzyme Technologies Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai Ii.
Charges
A charge registered on 11 Jun 2013 via Charge ID 10433741 with Dbs Bank Ltd. was fully satisfied on 03 Mar 2025.
Charges
A charge registered on 29 Jun 2022 via Charge ID 100595179 with Axis Bank Limited was fully satisfied on 01 Aug 2024.
Charges
A charge registered on 10 Feb 2022 via Charge ID 100542147 with Others was fully satisfied on 20 Apr 2024.
Ceased
Kedar Jagdish Desai ceased to be Director.
Ceased
Rajesh Kumar Sharma ceased to be Director.
Appointed
Vandana Ravindra Tilak was appointed as Director.
Charges
A charge registered on 25 Mar 2017 via Charge ID 100092007 with Hdfc Bank Limited was fully satisfied on 29 Mar 2023.
Charges
A charge registered on 08 Apr 2016 via Charge ID 100060365 with Others was fully satisfied on 13 Mar 2023.
Appointed
Nitin Jagannath Deshmukh was appointed as Director.
96 earlier events are in the company report.
News
Frequently asked questions
Advanced Enzyme Technologies is an active public limited company based in Thane, Maharashtra, India. The company works in industrial enzymes and biochemicals, within the chemicals and materials industry. It was incorporated on 15 March 1989 (37+ years old) and is registered under CIN L24200MH1989PLC051018. Listed on BSE: 540025 and NSE: ADVENZYMES.
Advanced Enzyme Technologies reported revenue of ₹745.76 Cr for FY 2025-26 (up 17.1% YoY) based on consolidated financials.
Advanced Enzyme Technologies has 9 current directors:
- Mukund Madhusudan Kabra - Whole-Time Director
- Vinodkumar Hiralal Jajoo - Director
- Rasika Vasant Rathi - Director
- Sunny Sharma - Director
- Pramod Kasat - Director
- Vasant Rathi - Director
- Nitin Jagannath Deshmukh - Director
- Vandana Ravindra Tilak - Director
- Pradip Bhailal Shah - Director
The latest financial statements of Advanced Enzyme Technologies on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 31 July 2026. Year-wise statements from 2015 are in the company report.
The GSTIN of Advanced Enzyme Technologies is 27AABCA4555E1ZX, registered in Maharashtra. The company has 3 GST registrations in all, of which 3 are active. Other active GSTINs include 27AABCA4555E2ZW (Maharashtra), 23AABCA4555E1Z5 (Madhya Pradesh).
The CIN (Corporate Identification Number) of Advanced Enzyme Technologies is L24200MH1989PLC051018. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Advanced Enzyme Technologies is a listed company as per MCA records. Its shares are listed on both BSE (code: 540025) and NSE (symbol: ADVENZYMES).
Advanced Enzyme Technologies has 31 court cases on record: 25 filed by the company and 6 filed against it. 3 are pending.
Advanced Enzyme Technologies was incorporated on 15 March 1989, making it 37+ years old. It is registered with the Registrar of Companies, Mumbai.
Advanced Enzyme Technologies has 28 deals on record (24 market trades, 2 secondary share transfers, 1 ipo), with disclosed funding of ₹30 Cr; the latest was in August 2025.
The peers of Advanced Enzyme Technologies by revenue are Novozymes South Asia Private Limited, Guaran Chemicals Private Limited, Sanzyme Biologics Private Limited, all in the Chemicals industry (Enzymes), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Pradip Bhailal Shah was appointed as Director on 12 Jun 2026. Kedar Jagdish Desai ceased to be Director on 31 Mar 2024. Rajesh Kumar Sharma ceased to be Director on 10 Aug 2023. Advanced Enzyme Technologies has 35 board changes on record in total.